Marketable Debt and Equity Securities - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended			6 Months Ended	9 Months Ended
	Jul. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 16, 2024
Equity Securities
Unrealized gain (loss) on equity securities		$ 9,162		$ (11,023)		$ (1,728)	$ (13,633)
Impairment on equity securities		$ 0		$ 0		$ (20,430)	$ 0
Zenas
Equity Securities
Impairment on equity securities					$ (20,400)
Astria | Common Stock | License
Equity Securities
Sale of common stock and pre-funded warrants, net of issuance cost (in shares)	253,958		443,909
Number of shares owned (in shares)		0		697,867		0	697,867
Astria/Catabasis | Technology License Agreement
Equity Securities
Unrealized gain (loss) on equity securities		$ 100		$ (600)		$ 1,300	$ (4,500)
INmune | License
Equity Securities
Unrealized gain (loss) on equity securities		$ (6,500)		(4,400)		$ (11,100)	800
INmune | Common Stock | License
Equity Securities
Number of shares owned (in shares)		1,885,533				1,885,533
Viridian | Technology License Agreement
Equity Securities
Unrealized gain (loss) on equity securities		$ 7,000		$ (6,100)		$ 700	$ (9,900)
Viridian | Common Stock | Technology License Agreement
Equity Securities
Number of shares owned (in shares)		717,144				717,144
Zenas
Equity Securities
Unrealized gain (loss) on equity securities		$ 8,600				$ 8,600
Zenas | Common Stock | Technology License Agreement
Equity Securities
Number of shares owned (in shares)								3,098,380